KIMBERLY LESLIE

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. pmc A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
    Shujie Yang
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e26343. 2011
  2. ncbi request reprint Epigenetic modification restores functional PR expression in endometrial cancer cells
    Shujie Yang
    200 Hawkins Drive, University of Iowa, Iowa City, IA 52242
    Curr Pharm Des 20:1874-80. 2014
  3. pmc The consequence of oncomorphic TP53 mutations in ovarian cancer
    Pavla Brachova
    Molecular and Cellular Biology Program, University of Iowa, Iowa City, IA 52242, USA
    Int J Mol Sci 14:19257-75. 2013
  4. pmc A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study
    Kimberly K Leslie
    University of New Mexico Health Sciences Center, Albuquerque, NM 87131, United States
    Gynecol Oncol 129:486-94. 2013
  5. pmc Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
    Kimberly K Leslie
    The University of Iowa, Iowa City, IA 52242, USA
    Gynecol Oncol 127:345-50. 2012
  6. pmc An exploratory study of the variables impacting preterm birth rates in New Mexico
    Kara M Gwin
    Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, NM, USA
    BMC Pregnancy Childbirth 12:53. 2012
  7. pmc Endometrial cancer
    Kimberly K Leslie
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA
    Obstet Gynecol Clin North Am 39:255-68. 2012
  8. pmc EGFR isoforms and gene regulation in human endometrial cancer cells
    Lina Albitar
    The Reproductive Molecular Biology Laboratory, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Mol Cancer 9:166. 2010
  9. pmc An inhibitor of K+ channels modulates human endometrial tumor-initiating cells
    Brandon M Schickling
    Department of Obstetrics and Gynecology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Cancer Cell Int 11:25. 2011

Research Grants

  1. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2003
  2. Targeted Therapy for Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2009
  3. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2002
  4. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2004
  5. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2005
  6. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2006
  7. Targeted Therapy for Endometrial Cancer
    Kimberly K Leslie; Fiscal Year: 2010

Collaborators

Detail Information

Publications11

  1. pmc A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
    Shujie Yang
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e26343. 2011
    ..We conclude that the addition of a PI3K inhibitor overcomes cellular resistance to mTORC1 inhibitors regardless of PTEN status, and thus substantially expands the molecular phenotype of tumors likely to respond...
  2. ncbi request reprint Epigenetic modification restores functional PR expression in endometrial cancer cells
    Shujie Yang
    200 Hawkins Drive, University of Iowa, Iowa City, IA 52242
    Curr Pharm Des 20:1874-80. 2014
    ....
  3. pmc The consequence of oncomorphic TP53 mutations in ovarian cancer
    Pavla Brachova
    Molecular and Cellular Biology Program, University of Iowa, Iowa City, IA 52242, USA
    Int J Mol Sci 14:19257-75. 2013
    ..An understanding of the pathological pathways altered by each mutation is necessary in order to design appropriate drug interventions for patients suffering from this deadly disease. ..
  4. pmc A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study
    Kimberly K Leslie
    University of New Mexico Health Sciences Center, Albuquerque, NM 87131, United States
    Gynecol Oncol 129:486-94. 2013
    ..A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer...
  5. pmc Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
    Kimberly K Leslie
    The University of Iowa, Iowa City, IA 52242, USA
    Gynecol Oncol 127:345-50. 2012
    ....
  6. pmc An exploratory study of the variables impacting preterm birth rates in New Mexico
    Kara M Gwin
    Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, NM, USA
    BMC Pregnancy Childbirth 12:53. 2012
    ..The goal of this study was to identify maternal risk factors for PTB in New Mexico, a poor state with a unique ethnic background, in order to identify populations at increased risk that would benefit from intervention...
  7. pmc Endometrial cancer
    Kimberly K Leslie
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA
    Obstet Gynecol Clin North Am 39:255-68. 2012
    ....
  8. pmc EGFR isoforms and gene regulation in human endometrial cancer cells
    Lina Albitar
    The Reproductive Molecular Biology Laboratory, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Mol Cancer 9:166. 2010
    ....
  9. pmc An inhibitor of K+ channels modulates human endometrial tumor-initiating cells
    Brandon M Schickling
    Department of Obstetrics and Gynecology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Cancer Cell Int 11:25. 2011
    ..abstract:..

Research Grants8

  1. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2003
    ....
  2. Targeted Therapy for Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2009
    ..These studies will form the basis for the rational design of multi-agent targeted regimens in the future which have the potential to significantly enhance therapeutic options for women with advanced endometrial cancer. ..
  3. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2002
    ....
  4. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2004
    ....
  5. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2005
    ....
  6. EGFR Blockade in Endometrial Cancer
    KIMBERLY LESLIE; Fiscal Year: 2006
    ....
  7. Targeted Therapy for Endometrial Cancer
    Kimberly K Leslie; Fiscal Year: 2010
    ..These studies will form the basis for the rational design of multi-agent targeted regimens in the future which have the potential to significantly enhance therapeutic options for women with advanced endometrial cancer. ..